Compare BYFC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BYFC | CRDF |
|---|---|---|
| Founded | 1946 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 82.5M |
| IPO Year | 2013 | 2012 |
| Metric | BYFC | CRDF |
|---|---|---|
| Price | $11.66 | $0.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.81 |
| AVG Volume (30 Days) | 1.7K | ★ 442.1K |
| Earning Date | 07-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.07 | N/A |
| Revenue | $184,000.00 | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.70 |
| P/E Ratio | $162.43 | ★ N/A |
| Revenue Growth | 18.71 | ★ 49.61 |
| 52 Week Low | $5.51 | $0.76 |
| 52 Week High | $12.35 | $3.31 |
| Indicator | BYFC | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 39.55 | 30.24 |
| Support Level | $9.29 | $0.88 |
| Resistance Level | $12.27 | $1.13 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 0.00 | 4.34 |
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.